- Home
- CTS vs NRIX Comparison
CTS vs NRIX Comparison
Compare CTS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTS
- NRIX
- Stock Information
- Founded
- CTS 1896
- NRIX 2009
- Country
- CTS United States
- NRIX United States
- Employees
- CTS N/A
- NRIX N/A
- Industry
- CTS Electrical Products
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- CTS Technology
- NRIX Health Care
- Exchange
- CTS Nasdaq
- NRIX Nasdaq
- Market Cap
- CTS N/A
- NRIX 1.1B
- IPO Year
- CTS N/A
- NRIX 2020
- Fundamental
- Price
- CTS $42.14
- NRIX $12.15
- Analyst Decision
- CTS
- NRIX Strong Buy
- Analyst Count
- CTS 0
- NRIX 17
- Target Price
- CTS N/A
- NRIX $30.82
- AVG Volume (30 Days)
- CTS 146.3K
- NRIX 946.2K
- Earning Date
- CTS 04-30-2025
- NRIX 04-09-2025
- Dividend Yield
- CTS 0.38%
- NRIX N/A
- EPS Growth
- CTS N/A
- NRIX N/A
- EPS
- CTS 1.89
- NRIX N/A
- Revenue
- CTS $515,770,999.00
- NRIX $54,549,000.00
- Revenue This Year
- CTS $5.31
- NRIX $1.77
- Revenue Next Year
- CTS $6.01
- NRIX $6.62
- P/E Ratio
- CTS $22.16
- NRIX N/A
- Revenue Growth
- CTS N/A
- NRIX N/A
- 52 Week Low
- CTS $41.23
- NRIX $11.90
- 52 Week High
- CTS $59.68
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- CTS 38.65
- NRIX 30.68
- Support Level
- CTS $41.80
- NRIX $12.20
- Resistance Level
- CTS $44.08
- NRIX $13.10
- Average True Range (ATR)
- CTS 0.93
- NRIX 0.77
- MACD
- CTS 0.23
- NRIX 0.01
- Stochastic Oscillator
- CTS 31.93
- NRIX 5.23
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.